Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shanghai ChemPartner Aids Agios’ Cancer Research Breakthrough

publication date: Dec 9, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai ChemPartner, one of ShangPharma’s several subsidiaries, said its scientists contributed to the breakthrough cancer research announced by Agios Pharmaceuticals, with whom ChemPartner has an ongoing relationship. In the November 22 online issue of Nature, Agios scientists published an article entitled "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG)." Their research, at least partly carried out at ChemPartner, showed the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene, revealing new possibilities for novel cancer treatments. More details...

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...